Prime Medicine, Inc.

PRME · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $0.6B · 146 employees
65
SEC Filings
$3.55
Close 2026-05-29
146
Employees

Business Summary

PART I Overview We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks. We believe Prim...

Latest Stock Quote

PRME 2026-05-29 $3.55 O:$3.39 H:$3.56 L:$3.26 Vol:3.3M VWAP:$3.4468
origin leaf: 33d563e6542a6f61ca6fc3b7e71c7fd313b0d880985597291ff4dd6d6f783301

Next Earnings

Q2 FY2026 — expected 2026-09-16

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-032025-12-310001628280-26-013569EDGAR132K words
2025-02-282024-12-310001628280-25-008884EDGAR—
2024-03-012023-12-310001628280-24-008116EDGAR—
2023-03-092022-12-310001628280-23-007266EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-072025-09-300001628280-25-050422EDGAR20K words
2025-08-072025-06-300001628280-25-038619EDGAR—
2025-05-082025-03-310001628280-25-023486EDGAR—
2024-11-122024-09-300001628280-24-047130EDGAR—
2024-08-082024-06-300001628280-24-035893EDGAR—
2024-05-102024-03-310001628280-24-022473EDGAR—
2023-11-032023-09-300001628280-23-036777EDGAR—
2023-08-072023-06-300001628280-23-027772EDGAR—
2023-05-112023-03-310001628280-23-017423EDGAR—
2022-11-142022-09-300001628280-22-029889EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-030001628280-26-013565EDGAR2K words
2026-01-120001628280-26-001773EDGAR—
2025-11-070001628280-25-050415EDGAR—
2025-09-080001894562-25-000056EDGAR—
2025-08-070001628280-25-038617EDGAR—
2025-08-050001628280-25-037840EDGAR—
2025-07-310001628280-25-037076EDGAR—
2025-07-300001628280-25-036705EDGAR—
2025-07-150001628280-25-034971EDGAR—
2025-06-050001628280-25-029646EDGAR—

65 total filings indexed. 41 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001894562
TickerPRME
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
Websitehttps://www.primemedicine.com
Listed2022-10-20

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 12854f1b12bb0d6cbfecb84d506fee0ea3aaa1a5f714924b2e6279c2fecc70d3
parent: 0583f2520aa8a3c34ea98d384d783509c165371148deeef528d0b3bc51d4a426
content hash: 53e6d4863a73c3af3959401aaa03764c4f8f7c0301a38256e6d368a9763830b7
signed: 2026-06-02T19:02:21.259Z
sources: 15 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf